UPS und DOWNS bei den AMI-Werten!

[actr]

Identix Incorporated
12.01.06 20:19 Uhr

7,13 USD

+23,36 % [+1,35]

http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=IDNX.NAS&lColors=0x000000&sSym=IDNX.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=IDNX.NAS&lColors=0x000000&sSym=IDNX.NAS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=IDNX.NAS&lColors=0x000000&sSym=IDNX.NAS&hcmask=

Börse
NASDAQ

Aktuell
7,13 USD

Zeit
12.01.06 20:19

Diff. Vortag
+23,36 %

Tages-Vol.
131,39 Mio.

Gehandelte Stück
20 Mio.

Viisage and Identix to Merge to Create Biometric Identity Solution Leader

BILLERICA, Mass. & MINNETONKA, Minn., Jan 12, 2006 (BUSINESS WIRE) -- Viisage Technology, Inc. (Nasdaq: VISGD) and Identix Incorporated (Nasdaq: IDNX):
-- Establishes the Industry's Most Comprehensive Multi-Modal Biometric Platform for Securing and Protecting Personal Identities

-- Management Team to be Led by Robert V. LaPenta as Chairman and Chief Executive Officer

-- Combined Pro Forma Calendar 2006 Estimated Revenue of $220 Million and EBITDA of at Least $40 Million

Identity solutions provider Viisage Technology, Inc. (Nasdaq: VISGD) and biometric technology innovator Identix Incorporated (Nasdaq: IDNX) today announced they have entered into a definitive agreement to merge in an all stock transaction. The combined company will blend two complementary approaches to solving the challenge of protecting and securing personal identities by establishing the industry's most comprehensive single platform for multi-modal finger, face, skin and imaging identity solutions. The combination has been approved by the respective boards of directors of each company.

The combined company, on a pro forma calendar 2006 basis, is expected to have revenue of approximately $220 million and EBITDA of at least $40 million, including synergies and operating efficiencies.

Under the terms of the transaction, Identix shareholders will receive a fixed exchange ratio of 0.473 newly issued shares of Viisage stock for each share of Identix stock. The transaction is expected to be tax-free to shareholders of both companies for U.S. federal income tax purposes. Based on Viisage's closing stock price of $17.69 on January 11, 2006, the transaction is valued at approximately $770 million on a fully diluted basis.

Upon completion of the transaction, current Identix shareholders will own approximately 59 percent of the combined company and current Viisage shareholders will own approximately 41 percent of the combined company. The combined company's board of directors will consist of 12 directors, with seven of the members designated by Viisage and affiliates and five designated by Identix. The headquarters of the combined company will be in Stamford, Connecticut. In addition, certain affiliates of both Viisage and Identix have agreed to vote their shares in favor of the merger.

Following the close of the transaction, the company expects to evaluate alternatives for repurchasing outstanding shares, including the potential issuance of convertible debt.

"The combination of Identix' advanced multi-biometric search technology with Viisage's expertise in secure credentials, document authentication and verification will create a global leader in biometric security, providing end-to-end identity solutions for state, local, national and foreign government use, as well as a wide application across the commercial sector," said Robert V. LaPenta, Chairman of the Board of Viisage. "With its proven technology, strength of management and services, and marquee customer base, the combined entity has the ability to achieve significant revenue growth and profitability."

Upon completion of the merger, Mr. LaPenta, Viisage's Chairman, will become Chairman and Chief Executive Officer of the combined company. Mr. LaPenta is the Chairman, CEO and founder of L-1 Investment Partners, Chairman of the Board of Viisage, and former President, Chief Financial Officer and co-founder of L-3 Communications. Dr. Joseph J. Atick, currently Chief Executive Officer of Identix, will become Vice Chairman of the combined company's Board of Directors and Chief Strategic Officer.

"This is a fantastic opportunity for the new company's shareholders, employees and customers and will create a formidable combination in the identity solution / management and biometrics sector," said Dr. Joseph J. Atick, CEO of Identix.

Unlocking the Potential of Strong Synergies

Driven by a combined global sales force, the merger unlocks the potential of both organization's strengths in biometrics, credentialing and imaging solutions and offers many natural synergies. For example, Viisage and Identix each have current customer relationships today with the Department of State, with Identix providing biometric facial recognition products for the U.S. VISA program and Viisage acting as the sole source provider for U.S. passports.

The combined technologies are uniquely suited to support multiple identity programs including visa and passport issuance, border control and security, voting program integrity, secure logical access for enterprise and government, and the myriad of government-related access card requirements. In addition, the new company also can successfully meet rigorous government mandates including HSPD12, TWIC, WHTI, US- VISIT, Registered Traveler, HAZMAT, Real ID and ePassport, among others.

The merger positions the new company as a market leader in the biometrics sector. The combined capabilities allow the new company to effectively compete for approximately 80 percent of a market opportunity projected by Frost & Sullivan to reach $3.5 billion by 2008*.

The transaction is expected to close in the second calendar quarter of 2006 and is subject to customary regulatory approvals and other closing conditions, including approval by Viisage and Identix shareholders at their respective stockholder meetings.

Bear, Stearns & Co. Inc. is serving as financial advisor to Viisage, while USBX Advisory Services LLC provided a fairness opinion to the Viisage Board. Janney Montgomery Scott LLC is serving as financial advisor to Identix and has provided a fairness opinion to the Identix Board.

[actr]

Ultralife Batteries, Inc.
12.01.06 21:51 Uhr

12,91 USD

+24,02 % [+2,50]
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=ULBI.NAS&lColors=0x000000&sSym=ULBI.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=ULBI.NAS&lColors=0x000000&sSym=ULBI.NAS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=ULBI.NAS&lColors=0x000000&sSym=ULBI.NAS&hcmask=

Börse
NASDAQ

Aktuell
12,93 USD

Zeit
12.01.06 21:52

Diff. Vortag
+24,21 %

Tages-Vol.
16,67 Mio.

Gehandelte Stück
1,4 Mio.


Ultralife Batteries Receives $1.4 Million Production Order from General Dynamics for Land Warrior Batteries and Chargers

NEWARK, N.Y., Jan 12, 2006 (BUSINESS WIRE) -- Ultralife Batteries, Inc. (NASDAQ: ULBI) has received a battery and charger production order from General Dynamics C4 Systems valued at approximately $1.4 million. The contract is for lithium ion rechargeable batteries as well as vehicle, bulk and individual Soldier-based chargers, part of the equipment being delivered to General Dynamics for use in a Stryker battalion operational assessment.
Land Warrior is an integrated, modular fighting system that uses technology to enhance individual soldiers' close-combat tactical awareness, lethality and survivability. The system includes weapon-mounted sensors, an integrated helmet assembly, a communications-navigation computer system and software for friendly-force tracking and command/control programs. Featuring seamless connectivity to the General Dynamics Stryker combat vehicle, the Land Warrior - Stryker Interoperable portion of the program will undergo a comprehensive operational assessment and a Limited User Test this summer.

In February 2004, Ultralife received a $2.7 million development contract from General Dynamics to design and develop the batteries and chargers to equip Land Warrior ensembles with an advanced man-portable power system. Deliveries against the new production order will begin this month and be completed by the end of March.

John D. Kavazanjian, Ultralife's president and chief executive officer said, "Our power systems engineering services capabilities, combined with our superb track record of developing and supplying industry-leading battery and charger designs demonstrates our ability to move highly-engineered products from design into production. These capabilities are proving to be a key competitive advantage for us as the demand for our products continues to grow."

The products being supplied include: Ultralife's UBBL06 (LI-145) Rechargeable battery, which is a lightweight, rugged, high-energy 16.8 volt, 9.4 Ah lithium ion rechargeable SMBus v1.1 compliant smart battery with a state-of-charge indicator; the CH0006 3-Bay Vehicle Based Charger, which is a 3-battery rugged Smart Level-3 charger mounted in different variants of the Stryker Vehicle; the CH0008 Individual Soldier Based Charger Kit, which is a rugged Smart Level-2 charger with global input voltage and frequency capability; and the CH0017 12-Bay Bulk Charger Kit, which is a 12-battery rugged Smart Level-3 charger with AC and DC power source options, having the capability for various field uses, on a vehicle or in a depot setting.

About Ultralife Batteries, Inc.

Ultralife is a global provider of high-energy power systems for diverse applications. The company develops, manufactures and markets a wide range of non-rechargeable and rechargeable batteries, charging systems and accessories for use in military, industrial and consumer portable electronic products. Through its portfolio of standard products and engineered solutions, Ultralife is at the forefront of providing the next generation of power systems. Industrial, retail and government customers include General Dynamics, Philips Medical Systems, General Motors, Energizer, Kidde Safety, Lowe's, Radio Shack and the national defense agencies of the United States, United Kingdom, Germany and Australia, among others.

Ultralife's headquarters, principal manufacturing and research facilities are in Newark, New York, near Rochester. Ultralife Batteries (UK) Ltd., a second manufacturing facility, is located in Abingdon, England. Both facilities are ISO-9001 certified. Detailed information on Ultralife is available at the Company's web site, www.ultralifebatteries.com.

[actr]

Bad Ticker

By Lawrence Carrel
January 12, 2006


--------------------------------------------------------------------------------
Apogee Technology Inc. (ATA1)

--------------------------------------------------------------------------------
Share price as of Wednesday`s close: $1.65
Share price now: $1.92
Change: 16.4%
Volume: 494,600 shares, daily average 31,500 shares
Last time this high: April 26, 2005
52-week high: $4.39
52-week low: 70 cents
Forward P/E before news: n/a
Forward P/E after news: n/a

--------------------------------------------------------------------------------

DUE DILIGENCE FOR investors ought to include finding the right ticker symbols before buying stocks.
Apogee Technology (ATA2) shares jumped another 16% to $1.92 Thursday, making the tiny sensor maker`s shares a three-day double. Not bad for a company under threat of delisting from the American Stock Exchange. Through Monday the stock had plunged 80% from the beginning of 2005 to close at 91 cents.

But buyers may not be getting what they think.

According to Streetinsider.com, a Birmingham, Mich., news analysis service that follows momentum stocks and tracks rumors, "the run-up in Apogee Technology is related to a Jim Cramer recommendation on ATS Automation Tooling Systems, which trades under the same symbol in Canada. Traders are apparently buying ATA on the Amex thinking it is the correct company, but it is not." Cramer hosts a popular CNBC stock-picking show called "Mad Money."

"Just look at the volume," says Lon Juricic, president of StreetInsider.com. "On Monday, Apogee`s volume was 2,700 shares. Then Cramer comes on and recommends the other stock and the volume surges to 733,000 on Tuesday. There`s no news, so to me it seems pretty obvious people got confused. But, it`s weird the stock keeps going up. You`d think someone, the company, Cramer or the Amex would put out a statement."

On Monday`s program, Cramer advised viewers to buy solar energy stocks, and one in particular. "I think you should buy ATS Automation Tooling Systems. That`s ATA.CN [on the Canadian Stock Exchange]," said Cramer, according to a transcript of the show. "It trades in Canada. That`s where you should buy it. I don`t want you buying the [American Depositary Receipt] on this one, because it trades on the pink sheets."

Based in Cambridge, Ontario, ATS Automation Tooling Systems makes mechanized manufacturing and test systems, as well as energy cells and modules. Solar products accounted for 18% of revenues for the year ended March 2005, according to James Bradford, an analyst with Toronto broker Blackmont Capital, who initiated coverage of the stock last week with a Buy recommendation.

"I think ATS will experience a turnaround in the core automation business," says Bradford. "Also the solar group is expected to grow stronger in terms of revenue and there`s the potential for unlocking shareholder value by spinning off the solar group."
For its fiscal second quarter ended Sept. 30 ATS posted a loss of $3.3 million Canadian dollars on revenues of C$154.5 million, compared with a year-earlier profit of C$432,000 on sales of C$180.3 million. The company blamed the loss on a sluggish U.S. automotive industry, which supplies a large part of the company`s revenues. ($1 equals 1.16 Canadian dollars.)

Shares of ATS, which closed at C$16.25 on the Toronto Stock Exchange Monday, added 3% on Tuesday. On Thursday, the stock rose to C$17.10.

Until October, Apogee had made semiconductors used in audio amplification. Now it makes pressure sensors for the automotive, consumer and medical markets with a proprietary technology it calls Micro-Electromechanical Systems, or MEMS.

For the third quarter the Norwood, Mass., company posted a net loss of $1.6 million compared with a year-earlier loss $449,000. Revenues fell 24% to $1.5 million. The company has posted just one annual profit in the past five years. As of Sept. 30 it had $812,485 in cash, down from $1.9 million at the end of 2004. In October the company sold its SigmaTel audio division, which included the amplifier technology, for $9.4 million and paid off $2.6 million in debt.

In early October, Price Target Research, an independent firm in Chicago, downgraded its rating on the stock to Unfavorable from Neutral.

"Our ratings are mainly driven by a [proprietary valuation] ratio on the potential for further appreciation," says Phillip Hofmann, senior vice president of Price Target Research. "This ratio has not been favorable for Apogee and we haven`t seen anything that would cause that assessment to be changed. Based on a quantitative view of their fundamental position, there is nothing that has happened this week to change our view."

For most of 2005 the company was under the threat of delisting from the Amex for failing to file its 2004 annual report and results for the March 2005 quarter. It filed those reports in August, but it`s unclear whether the delisting threat has been lifted. The Amex did not respond by press time.

So are investors buying Apogee in a wave of confusion? The company hasn`t released significant news since its November earnings results. Its last press release, dated Dec. 6, merely announced an exhibition of its new line of sensors.

Apogee officials couldn`t be reached for comment.

"This is a company with a lot of moving parts," says Adam Lowensteiner, managing director of Microcapreport.com, an online newsletter focusing on microcaps based in Bergenfield, N.J. "The micro-electromechanical systems is an interesting technology with multiple applications that can be used in consumer and medical markets. They are miniature pressure sensors with multiple advantages over other technologies on the market. After selling the amplifier division it has about $8 million in working capital, which should prevent it from being delisted."

Quote:
"Do they have an obligation to come out and talk about the stock price and do they actually know that this is occurring? We`re not sure," says Joe Romo, a regulatory analyst at the NASD/Amex Regulation Division. "It`s not like Apogee put out a press release. The NASD will conduct a thorough review of this situation."



http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&€cy=&&lSyms=ATA.ASE&lColors=0x000000&sSym=ATA.ASE&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&€cy=&&lSyms=ATA.ASE&lColors=0x000000&sSym=ATA.ASE&hcmask=

http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=MACD&ind2=RSI&€cy=&lSyms=ATA.ASE&lColors=0x000000&sSym=ATA.ASE&hcmask=

[actr]

DRAXIS Receives FDA Approval for Diagnostic Iodine I-131 Capsules Product will supplement existing line of products for treating thyroid cancer

MISSISSAUGA, ON, Jan 13, 2006 /PRNewswire-FirstCall via COMTEX/ -- The radiopharmaceutical business unit of DRAXIS Health Inc. (TSX: DAX) (NASDAQ: DRAX) has received approval from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application for Sodium Iodide I-131 Capsules USP, Diagnostic - Oral.
These diagnostic sodium iodide I-131 capsules are intended to be used by physicians to perform the radioactive iodide (RAI) uptake test to evaluate thyroid function prior to treatment with stronger therapeutic doses of sodium iodide I-131. Diagnostic doses of sodium iodide I-131 may also be employed in localizing metastases associated with thyroid malignancies. The diagnostic capsules, which are supplied in a gelatin capsule for oral administration, will be produced by DRAXIMAGE, a division of DRAXIS Specialty Pharmaceuticals Inc., the Montreal-based subsidiary that serves as the operating arm of DRAXIS Health Inc.

DRAXIMAGE plans to introduce the new diagnostic capsules into the U.S. market during the first half of 2006, targeting qualified, approved nuclear physicians and/or radiopharmacists. The DRAXIMAGE sodium iodide I-131 diagnostic capsules will be supplied in several different strengths of radioactivity and DRAXIMAGE will employ a system of color-coding to allow each patient to be administered the precise dose of radioactive iodine prescribed by their physician.

The Sodium Iodide I-131 Capsules USP, Diagnostic - Oral are a further addition to the existing line of I-131 radiopharmaceutical products produced by DRAXIMAGE, including its widely used kit for the preparation of Sodium Iodide I-131 Capsules and Oral Solution for the treatment of thyroid cancer and hyperthyroidism. The FDA-approved kit product for therapeutic use was introduced to the U.S. market in 2003.

Thyroid Cancer

--------------

The thyroid gland is at the base of the throat and makes important hormones that help the body function normally. According to the website of the American Cancer Society (www.cancer.org) thyroid cancer is one of the most common endocrine cancers and is one of the few cancers for which incidence rates in the U.S. have increased over the past several years at a rate of approximately 2 percent per 100,000 people per year. They further estimate that in the year 2005 about 25,690 new cases of thyroid cancer will be diagnosed in the United States. The website states that thyroid cancer would seem to be much more common in women (approximately 75% of new cases) than in men and it mainly affects younger people, between the ages of 20 and 56. According to the same source, thyroid cancer is one of the least deadly cancers with a 5-year survival rate of nearly 97% for all cases.

About DRAXIS Health Inc.

DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc., provides products in three categories. Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and creams. Non-sterile products are produced as solid oral and semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications. Pharmaceutical contract manufacturing services are provided through the DRAXIS Pharma division and radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE division. DRAXIS Specialty Pharmaceuticals Inc. employs over 500 staff in its Montreal facility.


http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=DRAX.NAS&lColors=0x000000&sSym=DRAX.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=DRAX.NAS&lColors=0x000000&sSym=DRAX.NAS&hcmask=

http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=DRAX.NAS&lColors=0x000000&sSym=DRAX.NAS&hcmask=

[actr]

PHAZAR CORP
13.01.06 20:37 Uhr

16,97 USD

+61,31 % [+6,45]

http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=ANTP.NAS&lColors=0x000000&sSym=ANTP.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=ANTP.NAS&lColors=0x000000&sSym=ANTP.NAS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=ANTP.NAS&lColors=0x000000&sSym=ANTP.NAS&hcmask=

Börse
NASDAQ

Aktuell
16,96 USD

Zeit
13.01.06 20:38

Diff. Vortag
+61,22 %

Tages-Vol.
77,97 Mio.

Gehandelte Stück
5,1 Mio.

Phazar Edging Back from Fresh Extended-Hours Highs in Pre-Market

Boston, Jan 13, 2006 (MidnightTrader via COMTEX) -- Phazar (ANTP) is recently edging back from a pre-market high of 14.70, but still maintaining lofty upside momentum near 14 to 14.30.
Today's early strength above the 14 level firmly outpaces an after-hours high of 13.86 recorded Thursday night after the company posted an increase in Q2 results. It closed last night's session up 28.3% at 13.50.

Second quarter financial results announced by PHAZAR CORP

Jan 13, 2006 (M2 EQUITYBITES via COMTEX) -- PHAZAR CORP (Nasdaq: ANTP) announced on 12 January the results of operations for the quarter and six months ended 30 November 2005.
Net sales for the second quarter of 2005 were USD3.76m, as compared to USD3.29m for the corresponding quarter of 2004.

Net income for the second quarter of 2005 was USD0.69m or USD0.31 per share, as compared with net income of USD0.51m or USD0.22 per share for the corresponding period in 2004.

Net sales for the six months ended 30 November 2005 were USD6.944m, as compared with USD7.578m for the corresponding six months of 2004.

For the six months ended 30 November 2005 the company reported net income of USD1.22m or USD0.54 per share, as compared with net income of USD1.364m or USD0.61 per share for the corresponding six months of 2004.


(C)2006 M2 COMMUNICATIONS

[actr]

TYCO INTL LTD
13.01.06 21:07 Uhr

27,06 USD

-10,72 % [-3,25]
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=TYC.NYS&lColors=0x000000&sSym=TYC.NYS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=TYC.NYS&lColors=0x000000&sSym=TYC.NYS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=TYC.NYS&lColors=0x000000&sSym=TYC.NYS&hcmask=

Börse
NYSE

Aktuell
27,0699 USD

Zeit
13.01.06 21:07

Diff. Vortag
-10,69 %

Tages-Vol.
1,85 Mrd.

Gehandelte Stück
75 Mio.


Tyco Announces Intent to Separate Into Three Publicly Traded Companies

PEMBROKE, Bermuda, Jan 13, 2006 /PRNewswire-FirstCall via COMTEX/ -- Tyco International Ltd. (NYSE: TYC; BSX: TYC) today announced that its Board of Directors has approved a plan to separate the company's current portfolio of diverse businesses into three separate, publicly traded companies - Tyco Healthcare, one of the world's leading diversified healthcare companies; Tyco Electronics, the world's largest passive electronic components manufacturer, and the combination of Tyco Fire & Security and Engineered Products & Services (TFS/TEPS), a global business with leading positions in residential and commercial security, fire protection and industrial products and services.
The company intends to accomplish the separation through tax-free stock dividends to Tyco shareholders, after which they will own 100% of the equity in three publicly traded companies. Each company will have its own independent Board of Directors and strong corporate governance standards. Tyco expects to complete the transactions during the first quarter of calendar 2007.

According to Tyco Chairman and Chief Executive Officer Ed Breen, "In the past several years, Tyco has come a long way. Our balance sheet and cash flows are strong and many legacy financial and legal issues have been resolved. We are fortunate to have a great mix of businesses with market- leading positions. After a thorough review of strategic options with our Board of Directors, we have determined that separating into three independent companies is the best approach to enable these businesses to achieve their full potential. Healthcare, Electronics and TFS/TEPS will be able to move faster and more aggressively -- and ultimately create more value for our shareholders -- by pursuing their own growth strategies as independent companies."

Tyco's Board of Directors and senior leadership have evaluated a broad range of strategic alternatives, including continuation of Tyco's current operating strategy, sales of select businesses, and separation of only one of the businesses. The company and Board concluded that separating into three businesses is the best way to position these market-leading companies for sustained growth and value creation.

Three Leading Global Companies

TYCO HEALTHCARE

With 2005 revenue of nearly $10 billion, Tyco Healthcare is one of the foremost global providers of healthcare products and services. The company is well-positioned to capitalize on the attractive dynamics of the healthcare industry and to realize more robust growth. Its product portfolio includes advanced surgical instruments and supplies, respiratory care products, contrast media and diagnostic imaging products, needles and syringes, vascular therapies, sutures and wound care products, and generic pharmaceuticals. Healthcare has more than 40,000 employees.

This proposed separation will create a leading stand-alone healthcare company, which is expected to benefit from a focused and independent healthcare culture to help attract top industry talent and strategic partners, as well as increasing access to emerging healthcare-related technologies. This business will continue to be led by current Tyco Healthcare President Rich Meelia, who will become the company's Chief Executive Officer. Chief Operating Officer Kevin Gould and Chief Financial Officer Chuck Dockendorff will also continue in their current leadership positions with the company.

TYCO ELECTRONICS

Tyco Electronics is one of the world's largest suppliers of electronic components, including connectors, switches, relays, circuit protection devices, touch screens, magnetics, resistors, wire and cable, as well as fiber-optic and wireless components and systems. Electronics has 88,000 employees worldwide.

As a $12 billion stand-alone enterprise, Tyco Electronics will be positioned to move quickly and strategically as competition requires, and will be better able to participate in ongoing electronics industry consolidation. The company's Chief Executive Officer will be Tom Lynch -- current President of Tyco's Engineered Products & Services segment -- who brings broad experience in the communications and electronics industries. Dr. Juergen Gromer, who has led Tyco Electronics since 1999, will continue as President, and will also assume additional responsibilities as Vice Chairman. Jacki Heisse will continue to serve as the company's Chief Financial Officer.

TYCO FIRE & SECURITY/ENGINEERED PRODUCTS & SERVICES

TFS/TEPS will be led by Tyco International Chairman and CEO Ed Breen as well as Tyco International's Chief Financial Officer, Chris Coughlin. TFS/TEPS is an $18 billion world leader in electronic security solutions for residential, business, and governmental customers, fire protection and sprinkler systems, and industrial valves and controls. With more than 118,000 employees, TFS/TEPS has a large, stable recurring revenue base and generates strong cash flow. Dave Robinson will continue to serve as President of Tyco Fire & Security. Naren Gursahaney will succeed Tom Lynch as President of Engineered Products & Services.

Breen added, "We believe this separation is a logical next step in Tyco's evolution and we are absolutely convinced that this is the right decision for the long-term success of our businesses, employees and shareholders."

[actr]

SULPHCO INC
13.01.06 21:24 Uhr

16,60 USD

+10,67 % [+1,60]
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=SUF.ASE&lColors=0x000000&sSym=SUF.ASE&hcmask=

http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=SUF.ASE&lColors=0x000000&sSym=SUF.ASE&hcmask=

http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=SUF.ASE&lColors=0x000000&sSym=SUF.ASE&hcmask=

Börse
AMEX

Aktuell
16,60 USD

Zeit
13.01.06 21:24

Diff. Vortag
+10,67 %

Tages-Vol.
32,28 Mio.

Gehandelte Stück
2 Mio.

SulphCo Expands Management Team

Jan 11, 2006 (financialwire.net via COMTEX) -- January 11, 2006 (FinancialWire) SulphCo Inc. (AMEX: SUF), whose rivals include NATCO Group Inc (NYSE: NTG), has expanded its management team with the appointment of Michael Applegate as chief operating officer, responsible for overseeing day-to-day operations at the company.
Peter Gunnerman, who held the title of COO, continues as president of the company, focusing on strategy, implementation of the company's recently announced ventures and on the commercialization of SulphCo's ultrasound desulfurization process worldwide.

Applegate spent the majority of his career at Applegate Drayage Co., a tractor-trailer fleet operator in California, Nevada and Utah. The company employed more than 100 drivers, dock workers, mechanics and administrative staff. Applegate served as president, a position he held since 1988. Applegate has served as both president and chairman of the board of the California Trucking Association, the largest state trucking association in the United States. He also served on the board of the Nevada Motor Transportation Association.

"Mike has extensive management experience, which will prove valuable to our company," said Rudolf Gunnerman, SulphCo chief executive officer. "Expanding SulphCo's senior management team is an important priority for the company which we intend to address in 2006

[actr]

Phazar Locked on Stun

By Lawrence Carrel
January 13, 2006


--------------------------------------------------------------------------------
Phazar Corp. (ANTP1)

--------------------------------------------------------------------------------
Share price as of Thursday's close: $10.52
Share price now: $16.09
Change: 53.0%
Volume: 6.0 million shares, daily average 148,300 shares
Last time this high: Oct. 3, 2005
52-week high: $34.00
52-week low: $8.63
Forward P/E before announcement: n/a
Forward P/E after announcement: n/a

--------------------------------------------------------------------------------

AN ANTENNA MAKER'S earnings announcement got quite a reception.
Shares of Phazar (ANTP2) soared 53% to $16.09 Friday after the Fort Worth, Texas, company reported a 38% surge in fiscal second-quarter profits. Fueling the results were a pair of $2 million wireless communications contracts completed during the quarter for BAE Systems, Europe's largest defense contractor and Phazar's primary customer.

"Phazar is in a very good space in a very good industry, delivering the infrastructure for the wireless industry," says Michael Voellinger, vice president of wireless services for Telwares, a Pleasanton, Calif., consultant to the industry. "There are a lot of players involved and a lot of intelligent money is being invested in this space. It all boils down to wireless, from Bluetooth to WiMax to Mobile-Fi."

For its fiscal second quarter ended Nov. 30, Phazar posted late Thursday a profit of $698,773, or 31 cents a share, up from $504,753, or 22 cents, a year earlier. Operating income leapt 55% to $1.0 million as revenues climbed 14% to $3.8 million.

Phazar makes and installs antenna systems, towers and communication accessories. Most of the company's sales come from the U.S. government and its military contractors, such as BAE Systems. Formerly called British Aerospace, BAE is one of the Pentagon's top 10 suppliers, and contributed two-thirds of Phazar's sales for the six months ended Nov. 30, up from 53% of total sales for the fiscal year ended May 2005. Canada's Department of National Defence is Phazar's second-largest customer at 11% of total revenues. The U.S. government's direct purchases comprise 8% of sales.

The company said it's slowly adding private-sector customers. Still, with orders for equipment pending or in backlog, BAE Systems and the U.S. government are expected to remain major clients in 2006.

In Securities and Exchange Commission filings the 33-year-old company said: "We believe that Antenna Products enjoys a reputation for building quality products at a competitive price, because we continue to be asked to bid for new work. Because of our size and lack of significant liquid assets we are at a competitive disadvantage to larger companies that have greater resources to be able to bid a job at lower margins... On the other hand, our customers know us, know our personnel and can rely on us to build the antennas or towers or masts, etc., according to their specifications. We, therefore, compete on the basis of our reputation and history of building quality products at reasonable prices."

Cash provided from operating activities for the six months ended Nov. 30 was $1.1 million, vs. $2.7 million for the same time period in 2004. But accounts receivable as of Nov. 30 rose to $1.6 million from $663,098 as of May 31, primarily because of second-quarter sales to BAE Systems. Excluding the BAE Systems contracts, the company's order backlog stood at $1.6 million on Nov. 30. It has no debt and $3.8 million in cash.

"Phazar has good financials and some good contracts," says Telwares's Voellinger. "The opportunity is being in infrastructure and delivering wireless technology. That is huge. It is playing a piece in the infrastructure of wireless. Chips are another piece and security is another. I would rather be an infrastructure guy. It's much safer, and there's more money to be made."

Phazar announced in December the addition of four new mobile directional antennas to its instrument scientific medical (ISM) antenna product line. The ISM antennas are key components in the control systems used to operate automated rapid transit systems and monorails for urban and airport applications. These antennas are currently being deployed at DFW International Airport and San Francisco International Airport. The company added that this year it will provide antennas for the new terminal at Barajas International Airport in Madrid for the longest automated airport transportation system of its kind in Europe. It will also provide transit system antennas for the first driverless transit system in South Korea.

Phazar also reported in November that it added two multiport omni-directional antennas to its cellular and PCS product line. The dual models are capable of supporting up to four service providers per antenna at a site and the quad models are capable of supporting up to eight service providers per antenna at a site.

Phazar received notice on Nov. 3 from the Nasdaq that it was under threat of delisting. It had failed to comply with marketplace rules over the nomination of its board of directors. Six days later Phazar remedied the situation and the delisting threat was withdrawn.

The company's tiny float of two million shares likely contributed to Friday's run-up, as six million shares changed hands. Phazar management didn't return phone calls seeking comment.

Quote:
"Phazar seems to have a solid footing in this industry," says Telwares's Voellinger. "Some of the rapid growth and some of the market reaction is for companies across the board in this space. These companies will put up really good numbers as their revenues keep growing. This is your new bubble. Wireless technology is exploding. And anything that provides the infrastructure is exploding."

[actr]

Blodget’s Gedanken zu Google

Erinnert sich noch jemand an Henry Blodget? Als Analyst von Oppenheimer & Co. gab er der Aktie von Amazon.com im Dezember 1998 ein Kursziel von 400 Dollar, wurde alsbald zum Hohepriester des Internet und später zum Symbol der Internet-Blase. Jetzt warnt ausgerechnet Blodget vor allzu hohem Optimismus gegenüber Google.

Henry Blodget hat offenbar einiges gelernt in den letzten Jahren. Zum Beispiel, dass Aktien nicht grenzenlos in den Himmerl wachsen können. Und dass Fundamentaldaten wichtiger sind als Optimismus und Momentum am Aktienmarkt. Blodget sieht viele Aktien heute mit anderen Augen, und mit seiner Meinung hält er nicht hinterm Berg. Da ihm wegen übertriebenen Empfehlungen für schwache Aktien ein lebenslanges Berufsverbot im Wertpapierbereich auferlegt wurde, berichtet er lediglich nicht mehr als Insider über den Markt, sondern als „InternetOutsider“ – so der Name seines Blogs.

In diesem Blog hat sich Blodget nun den größten Internetgewinner der letzten Monate vorgeknöpft: Google. Und während die Aktie von acht Jahren vermutlich eine Kaufempfehlung nach der anderen bekommen hätte, postet der Ex-Analyst heute das Foto eines Furcht einflößenden Bören zu seinem Text. Auf dem Foto ist, wohlgemerkt, nur ein einzelner Bär zu sehen, was der Situation an der Börse ziemlich genau entspricht. Denn zumindest unter den Google-Beobachtern wimmelt es nach wie vor von Bullen: Im eben angebrochenen Jahr haebn schon fünf Analysten das Kursziel für die Suchmaschine angehoben, Mark Stahlman von Caris & Co. zuletzt auf – festhalten! – 2000 Dollar.

Das ist bekanntes Terrain für Blodget, der Google ein Kursziel von 100 Dollar gibt – nicht kurzfristig, wie er selbst schreibt, aber möglicherweise irgendwann.

Das Hauptrisiko für Google sieht Blodget im einseitigen Umsatzfluss. Dass der Verkauf von einzelnen Wörtern als Suchbegriffe fast den kompletten Umsatz für die Suchmaschine einbringt, sei gefährlich. Dass Google zahlreiche andere Produkte habe, verbessere die Situation nicht, denn Google Earth, die Bücherei und der neu vorgestellte Videodienst trügen kaum zum Ergebnis bei.

Blodget widmet sich in seinen Beobachtungen also allein dem Verkauf von Suchbegriffen. Dass für winzelne Wörter immer mehr bezahlt werde, ist für den Internet-Experten ein kurzfristiger Trend, der irgendwann auslaufen werde. Doch sieht Blodget nicht nur den Preis pro Wort rückläufig, sondern eines Tages auch die Investitionen der Unternehmen in Online-Werbung.

Welchen Schaden sinkende Einnahmen anrichten könnte, zeigt Blodget im Vergleich mit der Kostenstruktur bei Google aus. Das Unternehmen habe einen ungewöhnlich hohen Anteil an Fixkosten, so dass sinkende Einnahmen umso stärker auf die Bilanz durchschlagen könnten.

Mit einem Szenario, das Blodget für Google ebenso vorsieht, kennt sich der Ex-Analyst bestens aus: Betrug. Dass Internet-Unternehmen für Betrügereien besonders anfällig sind, ist bekannt, schließlich fällt eine Beurteilung von Aktiva schwer, wo nicht mit Waren, sondern mit Information und Hinweisen gehandelt wird. Käme es aber zu Betrugsfällen bei Google, würden Unternehmen und Aktie umso ärger getroffen, je höher sie zur Zeit gejubelt würden.

Um Google-Anleger nun nicht in alle Winde zu verjagen, macht Blodget in seinem Blog eines klar: Ob und wann sich die Schreckensszenarien für die Suchmaschine einstellen, wisse er nicht. Investment-Hinweise wolle – und per Gericht darf – er darüber hinaus auch nicht geben, und so bleibt der Blog einfach eine von vielen Meinungen. Allerdings immer noch die Meinung von einem, der die Sonnen- und die Schattenseite der Internet-Aktien besser kennt als alle anderen.

Lars Halter

[actr]

Zacks.com announces that Donald Rowe highlights the following stocks: AAR Corporation, Administaff, Inc., NetLogic Microsystems, Inc. and UbiquiTel, Inc.

CHICAGO, Jan 16, 2006 (BUSINESS WIRE) -- Donald Rowe, editor of the Wall Street Digest newsletter, says 2006 will be a super year for the economy and the stock market, and he recommends AAR Corporation (NYSE:AIR), Administaff, Inc. (NYSE:ASF), NetLogic Microsystems, Inc. (Nasdaq: NETL) and UbiquiTel, Inc (Nasdaq: UPCS)


Sampling of Buy Recommendations:

AAR Corporation (NYSE:AIR) is a worldwide leader in supplying aftermarket products and services to the global aerospace/aviation industry. It provides aircraft, engines and engine parts; airframe and accessories products; overhaul, repair and maintenance services and company-manufactured products to customers in all segments of this industry.

Administaff, Inc. (NYSE:ASF) is a leading personnel management company that serves as a full-service human resources department for small and medium-sized businesses throughout the United States.

NetLogic Microsystems, Inc. (Nasdaq: NETL) is a semiconductor company that designs, develops and markets high performance knowledge-based processors for a variety of advanced Internet, corporate and other networking systems, such as routers, switches, network access equipment and networked storage devices.

UbiquiTel, Inc. (Nasdaq: UPCS) is the exclusive provider of Sprint PCS digital wireless personal communications services to four midsize and smaller markets in the western and midwestern United States. The company's business strategy includes the following elements: capitalize on affiliation with Sprint PCS, capitalize on experienced management team, execute optimal network build-out plan, utilize strategic third party relationships in network build-out, implement effective operating structure with a focus on customer service, and focus on midsize and smaller markets.

Read Donald Rowe's commentary regarding the 2006 economy and stock market. Then discover more stocks by clicking: http://at.zacks.com/?id=85

[actr]

Reynolds and Reynolds Enhances CRM Solution to Increase Compatibility, Functionality Contact Management 3.2 Answers Dealers' Call for DMS-Neutral Technology

DAYTON, Ohio, Jan 16, 2006 /PRNewswire-FirstCall via COMTEX/ -- The Reynolds and Reynolds Company (NYSE: REY), a leading provider of software and services to the automotive retailing industry, has launched an enhanced version of its Web- based customer relationship management (CRM) solution.
Contact Management 3.2 now empowers dealers, regardless of their dealer management system provider, to manage the sales process through one CRM provider from inquiry to close -- and at every touch point with the consumer -- whether the customer is on the Web, on the phone, in the showroom or in the service lane.

"Our customers have shared with us their desire to work with a single CRM partner to provide a comprehensive suite of CRM solutions, allowing them to move away from multiple point products that do not work seamlessly with each other," said Jill Gehrhardt, CRM solutions executive, Reynolds and Reynolds. "Contact Management enables dealerships to automate their sales activities with CRM tools and conduct timely follow up and targeted marketing campaigns to build loyalty and repeat business."

With Reynolds Contact Management, dealerships can leverage each interaction with the customer and log that customer immediately into follow-up steps and processes. It helps dealerships to move customers from the Web into the showroom and through the sales process.


Key upgrades to Reynolds Contact Management solution include:


- DMS Neutral: Empowers larger dealer groups with multiple DMS providers

throughout their locations to leverage Contact Management across the

enterprise and derive more consistent reporting. Dealers can choose to

import existing customer data, such as demographic information and

sales and service history, into Contact Management.


- Desk Log Function: Equips the sales management team with a tool to

monitor floor traffic and personalize visits for prospects. Through an

on-screen dashboard, sales managers have a view of dealership sales

activity. Dashboard functions enable managers to access client records,

assign salespersons, add vehicles, update sales steps, add and edit

notes, and create a deal. The function provides key metrics such as

prospect count and sales steps completed.


- Call Tracking: Captures inbound and outbound phone calls to produce

reports that help management monitor sales activity and can improve

employee productivity. Additionally, this optional feature aids sales

managers in coaching their sales team on how to effectively call

customers. The product interfaces with a majority of private telephone

switch (PBX) systems.

Contact Management's architecture combines the advantages of ASP delivery and advanced technology to make the application flexible and easy-to-use.

Reynolds is an automotive retail CRM market leader. Reynolds has more than 10,000 deployed CRM applications across its Reynolds Web Solutions, Contact Management and other lead management solutions.

About Reynolds

Reynolds and Reynolds (http://www.reyrey.com) helps automobile dealers sell cars and take care of customers. Serving dealers since 1927, it is the leading provider of dealer management systems in the U.S. and Canada. The company's award-winning product, service and training solutions include a full range of retail Web and Customer Relationship Management solutions, e-learning and consulting services, documents, data management and integration, networking and support and leasing services. Reynolds serves automotive retailers and OEMs globally through its incadea solution and a worldwide partner network, as well as through its consulting practice.

[actr]

Protox receives FDA clearance to begin Phase I prostate cancer trial

VANCOUVER, Jan. 16, 2006 (Canada NewsWire via COMTEX) -- Protox Therapeutics Inc. announced today that the Investigational New Drug (IND) application for PRX302, the Company's lead product for the treatment of recurrent localized prostate cancer, has been cleared by the US Food and Drug Administration (FDA). As reported previously, the IND application was filed in December, 2005 and its clearance means that the Company may now proceed with the initiation of its Phase I clinical trial. PRX302 is the first of a novel class of targeted prodrugs based on the Company's PORxin(TM) platform. It is a therapeutic pore-forming toxin designed to be activated by prostate specific antigen (PSA), an enzyme which is produced and is active only in the prostate.
"Receiving FDA approval to proceed with our first Phase I clinical trial is a significant and exciting milestone for the growth of Protox and its clinical development programme," stated Dr. Fahar Merchant, President and CEO of Protox. "This milestone underscores the potential therapeutic benefit of our targeted PORxin(TM) platform originally developed by Dr. Tom Buckley, our Chief Scientific Officer."

Dr Merchant added that, "our ability to successfully reach this important goal was due to the commitment and considerable effort by Rosemina Merchant, our Vice President for Development and Regulatory Affairs, and the support from our development partners. We expect to leverage our advances with PRX302 to file an additional IND this year for the treatment of benign prostatic hyperplasia (BPH or enlarged prostate), an indication that is not adequately served by current treatments."

The Phase I clinical trial will be an open-label, dose-escalation study of PRX302 in patients with locally recurrent prostate cancer. Patient enrollment will commence in the next few weeks. The Phase I trial will be conducted at Scott & White Memorial Hospital in Temple, Texas and at least one additional site in the United States. The trial is expected to enroll approximately 24 patients and has been designed to determine safety, tolerability and therapeutic activity of PRX302.

About Prostate Cancer

Prostate cancer is one of the most common malignancies in North American men. It is estimated that nearly 250,000 men in North America will be diagnosed with prostate cancer this year. Every year, more then 30,000 men die of prostate cancer in the US alone.

Current treatment options for localized prostate cancer include surgery (radical prostatectomy), brachytherapy (implantation of radioactive seeds), and external beam irradiation. Unfortunately each of these therapies can result in erectile dysfunction, incontinence, urinary toxicity and rectal toxicity. PRX302 is being developed for the treatment of localized recurrent prostate cancer. At present there are no licensed drugs available for salvage therapy of purely local recurrence of prostate cancer.

About Protox Therapeutics

Protox Therapeutics Inc. is developing novel targeted cancer therapeutics based on engineered protein toxins. Its lead programme (PORxin(TM)) is based on pore forming protoxins such as modified proaerolysin. PORxins(TM) are inactive pro-drugs that are preferentially activated at the tumour site into potent toxins by cancer specific proteases, thereby causing cancer cell death. The Company works in partnership with research groups at the University of Victoria, Johns Hopkins University, Scott & White Hospital and other research institutions.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this press release. This press release contains certain forward-looking statements respecting the Company's business, capital, research and development, and potential future products, which statements can be identified by the use of forward looking terminology, such as "expect", "to generate", "moving forward", "intends", "committed to", "moving", "developing", "believe" or the negative thereof or any other variations thereon or, or that events or conditions "will,", "can", "to", "may," "could" or "should" occur, or comparable terminology referring to future events or results. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including, without limitation, the need for extensive additional research and development, which is costly and time-consuming and may not produce anticipated or useful results; scientific research and development risks; the risk of technical obsolescence; intellectual property risks; manufacturing and marketing risks; partnership/strategic alliance risks; the effect of competition; the need for regulatory approvals, including without limitation, FDA approvals, which is not assured; product liability and insurance risks; the need for future human clinical trials, the occurrence and success of which is not assured; changes in business strategy or development plans; and the need for additional capital, which may not be obtained; and the fact that the Company may not produce any products or if it does, that such products may not be commercially successful; any of which could cause actual results to vary materially from current results or the Company's anticipated future results. See the Company's prospectus and other documents filed with the TSX Venture Exchange and the Canadian Securities Administrators at www.sedar.com from time to time for a further discussion of these and other important risks and uncertainties that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no obligation to update the information contained in this press release.

[actr]

At the Request of the TSX Venture Exchange, China Diamond Corp. Clarifies Certain Disclosure Information on Its Exploration Projects in China

LONDON, ON, Jan. 16, 2006 (Canada NewsWire via COMTEX) -- China Diamond Corp., (TSX-V: CDC) has amended the disclosure in its January 3, 2006 news release, which relates to the Company's exploration and mine expansion programs for 2005 and its corporate development plans for 2006, in order to clarify and expand on the disclosure that was contained within.
The 701 Changma Diamond Mine Expansion Plan

-------------------------------------------

In December 2004 the Company initiated a major underground capital development program at the Mine by deepening the main decline to the -40 metre level (the bottom-most development horizon for mining Indicated Mineral Resources). The Company is pleased to announce that this program has now been completed. Tonnes processed at the Mine have steadily increased since August 2005, and are now at normal production levels of approximately 10,000 tonnes per month. It is anticipated that 2006 mine throughput will be approximately 118,000 tonnes producing close to 82,000 carats.

Since new management took over the helm of the Company in late 2003, it believes that the value of the diamonds produced at the Mine is not realized to its full potential until the existing processing plant facilities are improved. To this end, the Company commissioned an engineering study to evaluate a processing plant improvement and at the same time, assess a mine expansion scenario to improve the economics of the Mine. The study was completed in December 2005 by the Beijing General Research Institute of Mining and Metallurgy ("BGRIMM"), a First Class Engineering certificate holder in China. The study recommends that annual throughput be increased to 168,300 tonnes, which would result in the recovery of approximately 120,000 carats of diamonds per annum. Additionally, a dense medium separator ("DMS") and x-ray circuit has been recommended for installation in the processing plant. This circuit will update the plant with state-of-the-art technology, resulting in increased recovery of diamonds and better control over security aspects. The installation of inertia cone crushers to replace the existing ball mills is expected to reduce fragmentation of diamonds, and reduce electricity consumption and mine operating costs.

Total capital investment over the life of the Mine is estimated at US$2.9 million, with US$1.5 million required in the next two years. Funds after the next two years are required for continued underground mine development and sustaining capital, which will be financed from after-tax profits. The Company is planning to have an independent 43-101 technical report completed on the property during the first quarter of 2006.



Exploration Projects

--------------------


Diamond Portfolio


702 Diamond Project


During 2005, the Company and its joint venture partner have been actively pursuing the necessary permits and licenses to complete a bulk sampling program and future mining of the 702 deposit. Although an independent engineering study was completed by a Chinese engineering firm during 2005 that indicated the positive aspects of this project, the Company considers that it is prudent to collect a relatively large bulk sample to ascertain the valuation of the diamonds prior to any mine production decision. This will not only provide the necessary confidence in the diamond value but will also provide the necessary information for detailing the optimal mining and processing scenarios for future mine operations. The Company is currently assessing the optimal way to proceed with the bulk sample and once the method and costs are determined, may require additional financing.

703 Diamond Project

Exploration on the 703 project throughout 2005 identified a number of circular magnetic anomalies thought to represent the possible kimberlite source of the diamonds and kimberlite indicator minerals previously recovered from surface soil and stream sediment sampling. In addition, the Company initiated a detailed soil sampling survey and resistivity survey immediately over top of and down slope of the Dajingtou (A1) anomaly. The detailed soil sampling recovered 6 diamonds and over 1,200 kimberlite indicator minerals. To date, six holes have been drilled into this area that have so far recovered a number of pyrope garnets, chrome diopside and chromite grains, all of which are indicative of a kimberlite source rock (October 12 news release). However, due the complex nature of the geology, which hosts a number of cross-cutting faults that may have caused displacement of the original kimberlite rock, core drilling has yet to intersect the kimberlite source rock for the diamonds. However, given the extensive soil sampling and the obvious cluster of diamonds in a relatively small area of less than 2km2, the Company remains confident in the potential of this area hosting a diamondiferous kimberlite, and as such, continues to aggressively explore this area with soil sampling, geophysics and core drilling, which is currently ongoing.

The Company expects to receive 4 other exploration licenses early in 2006 that are in the proximity of the Dajingtou License where exploration work is currently ongoing. The exploration program for 2006, for the Dajingtou license as well as the remaining four licenses (once received) is currently funded in entirety.



Gold Portfolio


Huixian Gold-Copper Project


During 2005, the Company successfully discovered four gold-copper mineralized zones on the Huixian Project with associated alteration and sulfide mineralization, similar to that of the Huixian Mine (September 19, 2005 news release).

The Company is continuing detailed surface exploration on the newly discovered zones, consisting of trenching and ground geophysics to better define the geometry of the mineralized zones beneath the surface to target mineralized zones for future core drilling. In addition, the Company is planning to commence drilling on the Huixian Mine mineralization in order to collect additional information of the gold-copper mineralization at depth prior to updating the estimate of Mineral Resources. The surface work for the project is funded and ongoing, while the core drilling program expected to commence later in 2006 will require additional financing, the amount of which will be determined upon completion of the surface exploration.

In the past two months, a total of 40 surface muck pile samples were collected from the area of the past producing Huixian Mine. The assays (see following Table 1) provide an indication of the high grade gold-copper values within the deposit that correlate well with the known average grade of the deposit.



<<

[actr]

16.01.2006 15:11
Presse: General Motors hebt Einsparziel an
Der amerikanische Automobilkonzern General Motors Corp. (ISIN US3704421052 (Nachrichten/Aktienkurs)/ WKN 850000) hat Presseangaben zufolge sein Einsparungsziel weiter erhöht.

Wie die "Financial Times Deutschland" unter Berufung von Aussagen des Konzernchefs Rick Wagoner bei einer Rede vor Analysten berichtet, will der angeschlagene Automobilhersteller seine Kosten bis zum Jahr 2010 um insgesamt 14 Mrd. Dollar senken. Bislang lag das ursprüngliche Ziel bei Kosteneinssparungen von 7 Mrd. Dollar bis zum Jahr 2008. Gleichzeitig betonte Wagoner laut dem Bericht, dass die Sanierung des Nordamerikageschäfts mit einem extremen Gefühl der Dringlichkeit durchgeführt werden soll. Dabei dürfte die bereits angekündigte Streichung von 30.000 Stellen bei General Motors wohl erst der Anfang gewesen sein, hieß es weiter.

Der CEO des weltgrößten Automobilkonzerns steht derzeit angesichts wachsender Kritik der Aktionäre und Analysten zunehmend unter Druck. Durch das neue Einsparungsziel will Wagnoer diesen Vorgaben nun gerecht werden. Vor dem Hintergrund der derzeitigen tarifrechtlichen Rahmenbedingungen müssen jedoch Werksschließungen mit der Automobilgewerkschaft UAW abgestimmt werden. Der Abbau von Stellen ist derzeit laut dem Bericht aufgrund der aktuellen Tarifverträge nahezu unmöglich.

Ein Insolvenzverfahren stellt in diesem Zusammenhang nach Meinung einiger Beobachter einen Ausweg aus der Misere dar. Für Wagoner ist das keine Lösung, weil bei einem Insolvenzantrag die Konsumenten keine GM-Autos mehr kaufen würden: "Die geben bis zu 40.000 Dollar für ein Auto aus, das sie in den nächsten fünf Jahren verwenden wollen", wird Wagoner zitiert. Seiner Meinung nach zählt für Kunden Verlässlichkeit "bei der Garantie oder beim Rückverkauf".

Die Aktie von General Motors notierte zuletzt bei 20,37 Dollar.

[actr]

Altair Nanotechnologies Inc.
17.01.06 22:00 Uhr

3,25 USD

+38,89 % [+0,91]
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=ALTI.NAS&lColors=0x000000&sSym=ALTI.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=ALTI.NAS&lColors=0x000000&sSym=ALTI.NAS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=ALTI.NAS&lColors=0x000000&sSym=ALTI.NAS&hcmask=

Börse
NASDAQ

Aktuell
3,25 USD

Zeit
17.01.06 22:00

Diff. Vortag
+38,89 %

Tages-Vol.
50,40 Mio.

Gehandelte Stück
16 Mio.

Altair Nanotechnologies Lithium Ion Battery Cells Exceed HEV Power Requirements of U.S. FreedomCAR

RENO, NV, Jan 17, 2006 (MARKET WIRE via COMTEX) -- Altair Nanotechnologies Inc. (NASDAQ: ALTI) today announced that its battery research and development team successfully completed a testing program for lithium ion battery cells containing Altairnano's nano-structured lithium titanate electrode materials.
"The test results demonstrated that the performance of these lithium ion battery cells exceed the system-level power requirements set forth by the U.S. Council for Automotive Research FreedomCAR Energy Storage System Performance Goals for hybrid electric vehicle (HEVs), as well as those requirements published by major U.S. automakers," said Evan House, Ph.D., Program Director, Altairnano's Advanced Materials & Power Systems business unit. These power requirements can be viewed at: www.uscar.org/consortia&teams/consortiahomepages/con-usabc.htm

The battery cells using Altairnano's nano-structured lithium titanate electrode materials in battery cell tests developed for HEV applications demonstrate a useable state-of-charge range twice that of conventional nickel metal hydride (NiMH) batteries presently used in hybrid electric vehicles. Nano-structured lithium titanate electrode materials offer a near-term promise of lithium ion batteries that exhibit rapid charge and discharge, longer cycle life and more inherently safe performance than either currently available nickel metal hydride or lithium ion batteries. These results support the feasibility of a power lithium ion battery pack half the size of those currently being tested for HEV applications.

"We believe this phase of our testing program provides enough data to demonstrate that lithium-ion batteries utilizing our nano-structured battery electrode materials can have both the energy and power densities that exceed those of the nickel metal hydride (NiMH) batteries currently being used in HEVs," commented Altairnano President and CEO Alan J. Gotcher, Ph.D. "In our meetings with members of the automotive industry in the U.S. and abroad, we have been told that power-based lithium-ion batteries with the ability to discharge and charge rapidly, combined with greater cycle life and abuse tolerance, are desirable for the future of hybrid vehicles.

"This assessment," continued Dr. Gotcher, "was validated in the October 24, 2005, issue of Automotive News, when Japan's largest maker of nickel metal hydride batteries, used by Ford Motor Company and other carmakers of hybrid vehicles, stated that the future belongs to lithium-ion batteries. This sentiment was echoed in the article by Sanyo Electric Company, Toyota Motor Corporation, General Motors and Ford Motor Company executives."

The power of Altair's cell was first demonstrated and published in the September 2004 edition of the advanced energy industry standard, Journal of Power Sources. In that paper, authored by Dr. Du Pasquier and colleagues of the Rutgers University Energy Storage Group, battery cells using Altairnano's nano-structured battery electrodes demonstrated a three-minute full recharge and more than 9,000 cycles of sequential three-minute, 100 percent, recharges and discharges, validating the superior cycle life characteristics of Altairnano's nano-materials, when compared to traditional lithium ion batteries with a cycle life of 300 to 500 recharges and discharges.

The battery testing programs for applications targeting HEVs and electric vehicles are underway at a specially equipped facility located in the company's corporate headquarters in Reno, NV. Located in Anderson, Indiana, Altairnano's battery product application labs, with rapid prototyping and battery testing capabilities, is expected to be fully equipped and operational and to have its first battery cells manufactured by the end of January.

ABOUT ALTAIR NANOTECHNOLOGIES INC.

Altairnano is a leading supplier and innovator of advanced ceramic nanomaterial technology. Based in Reno, Nevada, Altairnano has assembled a unique team of materials scientists who, coupled in collaborative ventures with industry partners and leading academic centers, have pioneered an array of intellectual property and products.

Altairnano's robust proprietary technology platforms produce a variety of crystalline and non-crystalline nanomaterials of unique structure, performance, quality and cost. The company has scalable manufacturing capability to meet emerging nanomaterials demands. Altairnano's two divisions, Life Sciences and Performance Materials, are focused on applications where the company's nanotechnology may enable new high growth markets. The Life Sciences Division is pursuing market applications in pharmaceuticals, drug delivery, dental materials and other medical markets. The Performance Materials Division is focused on market applications in advanced materials for paints and coatings; air and water treatment, environmental sensing, and alternative energy -- including new lithium ion battery electrode materials. For additional information on Altairnano and its nanomaterials, visit www.altairnano.com.

[actr]

BioCryst Pharmaceuticals, Inc.
17.01.06 22:00 Uhr

22,41 USD

+17,70 % [+3,37]
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=BCRX.NAS&lColors=0x000000&sSym=BCRX.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=BCRX.NAS&lColors=0x000000&sSym=BCRX.NAS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=BCRX.NAS&lColors=0x000000&sSym=BCRX.NAS&hcmask=

Börse
NASDAQ

Aktuell
22,41 USD

Zeit
17.01.06 22:00

Diff. Vortag
+17,70 %

Tages-Vol.
382,44 Mio.

Gehandelte Stück
19 Mio.

BioCryst Receives FDA Fast Track Designation for Peramivir

Jan 17, 2006 /PRNewswire-FirstCall via COMTEX/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S Food and Drug Administration (FDA) has granted "fast track" designation for peramivir injection in the treatment of influenza infections, including highly virulent, life-threatening strains of influenza. Peramivir is an influenza neuraminidase inhibitor that, in preclinical studies, has shown potent, broad- spectrum activity against multiple strains of flu, including the H5N1 virus. On December 22, 2005, BioCryst announced that the FDA had given the company approval to begin human clinical trials using injectable peramivir.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO )

The fast track programs of the FDA are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. In correspondence with BioCryst, the FDA said that it agrees that the use of peramivir in the proposed indication of treatment of influenza infections, including highly virulent, life-threatening strains, meets the criterion of treating a serious life-threatening condition. Based on this conclusion, the FDA designated peramivir injection for influenza infection as a fast track product.

"The FDA's decision supports our belief in the potential of peramivir as an effective therapy for the treatment of influenza, including highly virulent, life-threatening strains like those associated with avian influenza," said Charles E. Bugg, Ph.D., Chairman and Chief Executive Officer of BioCryst. "We are initially developing the intravenous formulation of peramivir for the treatment of acutely ill influenza-infected patients and anticipate beginning Phase I clinical testing of the intravenous formulation early this quarter, at the NIH Clinical Center in Bethesda, Maryland. In addition, we are also conducting preclinical studies with intramuscular formulations, which will be directed initially at patients with seasonal influenza infections. We are pursuing both of these development programs in close collaboration with research groups at the National Institutes of Allergy and Infectious Diseases (NIAID) at the National Institute of Health (NIH)."

About BioCryst

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. BioCryst integrates the necessary disciplines of biology, crystallography, medicinal chemistry and computer modeling to effectively use structure-based drug design to discover and develop small molecule pharmaceuticals.

BioCryst's lead product candidate, Fodosine(TM), is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently in a Phase IIa trial for patients with T-cell leukemia and a combination IV and oral Phase I pharmacokinetic trial in healthy volunteers was recently completed. Results of the Phase IIa and the Phase I pharmacokinetic trial will assist in the design of a planned combination IV and oral Phase IIb pivotal clinical trial in patients with T-cell leukemia. The Company has requested a Special Protocol Assessment from the FDA for this planned trial. Additionally, Fodosine(TM) is currently being studied in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma (CTCL), a Phase II trial in chronic lymphocytic leukemia (CLL) and a Phase I/II trial in B-cell acute lymphoblastic leukemia (B-ALL). Fodosine(TM) has been granted Orphan Drug status by the U.S. Food and Drug Administration for three indications: T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias including T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for treatment of B-cell acute lymphoblastic leukemia (ALL). Additionally the FDA has granted "fast track" status to the development of Fodosine(TM) for the treatment of relapsed or refractory T-cell leukemia.

In August, 2005, BioCryst initiated a Phase Ib study with its second- generation PNP inhibitor, BCX-4208, to evaluate the safety, tolerability and pharmacokinetics of multiple oral doses of BCX-4208. In November, 2005 BioCryst announced it had entered into an exclusive licensing agreement with Roche to develop and commercialize BCX-4208 for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases.

Additionally, BioCryst has re-initiated clinical development of peramivir, an inhibitor of influenza neuraminidase, with a focus on intravenous and intramuscular delivery. Also, BioCryst has identified a clinical candidate, BCX-4678, in its hepatitis C polymerase inhibitor program, and is advancing this compound through preclinical testing with the goal of filing an IND in 2006. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.

[actr]

DANA CP
17.01.06 22:01 Uhr

5,40 USD

-20,59 % [-1,40]
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=DCN.NYS&lColors=0x000000&sSym=DCN.NYS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=DCN.NYS&lColors=0x000000&sSym=DCN.NYS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=DCN.NYS&lColors=0x000000&sSym=DCN.NYS&hcmask=

Börse
NYSE

Aktuell
5,40 USD

Zeit
17.01.06 22:01

Diff. Vortag
-20,59 %

Tages-Vol.
42,33 Mio.

Gehandelte Stück
7,5 Mio.


Dana Corporation Reports Third-Quarter 2005 Results

Jan 17, 2006 /PRNewswire-FirstCall via COMTEX/ -- Dana Corporation (NYSE: DCN) today reported financial results for both the quarter and nine months ended Sept. 30, 2005, and announced that it will file its Form 10-Q for the third quarter of 2005 later today. The filing and delivery of this report will eliminate any defaults related to late filing of the third-quarter financial statements under the company's financing agreements.
(Logo: http://www.newscom.com/cgi-bin/prnh/19990903/DANA )

Sales for the third quarter of 2005 were $2,396 million, compared to $2,114 million during the same period in 2004. The company recorded a net loss of $1,272 million, or $8.50 per share, for the quarter, compared to net income of $42 million, or 28 cents per share in the third quarter of 2004. Results for the quarter and nine months ended Sept. 30, 2004 have been restated, as previously disclosed in the 2004 Form 10-K/A filed on Dec. 30, 2005.


About Dana Corporation

Dana people design and manufacture products for every major vehicle producer in the world. Dana is focused on being an essential partner to automotive, commercial, and off-highway vehicle customers, which collectively produce more than 60 million vehicles annually. A leading supplier of axle, driveshaft, engine, frame, chassis, and transmission technologies, Dana employs 46,000 people in 28 countries. Based in Toledo, Ohio, the company reported sales of $9 billion in 2004. Dana's Internet address is: http://www.dana.com.

[actr]

If It Doesn't Fit...

By Lawrence Carrel
January 17, 2006


--------------------------------------------------------------------------------
AHPC Holdings, Inc. (GLOV1)

--------------------------------------------------------------------------------
Share price as of Friday's close: $3.00
Share price now: $3.62
Change: 20.7%
Volume: 343,154 shares, daily average 4,800 shares
Last time this high: Oct. 18, 2005
52-week high: $5.65
52-week low: $2.32
Forward P/E before announcement: n/a
Forward P/E after announcement: n/a

--------------------------------------------------------------------------------

THE ONLY THING missing from a disposable glove maker's rags-to-riches announcement is, well, riches.
Shares of AHPC Holdings (GLOV2) jumped 21% to $3.62 Tuesday after the maker of latex gloves reported winning a five-year federal supply contract. Financial details3 of the pact weren't disclosed by the Glendale Heights, Ill., company.

"The company solidified a deal that's good for five years," says Adam Lowensteiner, managing director of Microcapreport.com, an online newsletter based in Bergenfield, N.J. "That's why a lot of companies like working with the government. The feds give out long contracts that are easier on your sales cycles. The big questions are: How big is the deal, and does it take AHPC to profitability?"

The answers, from the looks of it, are "not very" and "unlikely," based on information we pieced together from the General Services Administration, the federal procurement agency that doles out contracts on behalf of government agencies, and the company's regulatory filings. AHPC didn't return phone calls seeking comment.

"The contract is worth a potential value of $125,000 over five years," says GSA spokeswoman Viki Reath. According to the GSA, there are no preferences or guarantees in the agreement, and AHPC will compete against other government contractors to win sales among federal agencies. For the fiscal year ended June 30, AHPC's revenues totaled $26.6 million.

Formerly known as WRP Corp., AHPC sells gloves for the food service, medical, dental, nursing home and retail industries through its wholly owned subsidiary, American Health Products. AHPC markets latex, vinyl and synthetic disposable gloves under the brand names DermaSafe, Glovetex and SafePrep. Latex-powdered gloves comprise 28% of revenues, while latex powder-free gloves bring in 27% and nonlatex gloves, 36%

The contract, which runs from Dec. 1, 2005, to Nov. 30, 2010, is for DermaSafe and Glovetex examination and specialty latex gloves.

"If it's a real contract why didn't the company tell us the dollar amount?" says Peter Cohan, president of Peter S. Cohan & Associates, a management-consulting and venture-capital firm in Marlborough, Mass. "It seems if the company knew the dollar amount of the contract, it would disclose it. That would add to the credibility of the announcement and give investors a view into how much it's worth."

Recent earnings statements show lackluster results. For the fiscal first quarter ended Sept. 30, AHPC posted a net loss of $498,556, or 41 cents a share, vs. a net loss of $373,649, or 39 cents, for the year-earlier period. Revenues climbed 5.7% to $6.9 million. A 29% revenue increase in the company's health-care business was offset by increased costs for raw materials, primarily latex and low-density polyethylene. Gross margins fell to 20.7% from 23.2% a year earlier.

The company has produced a profit in just one of its past five quarters, and that came from a one-time gain from the sale of its Indonesian manufacturing business. And while annual losses have steadily decreased over the past two years, so have annual sales — they're half of what they were in 2001.

Other concerns loom. In its 2005 annual report AHPC said "during the process of responding to a recent SEC comment letter, the company's management identified an error which led to the identification of a material weakness within the company's financial reporting and disclosure controls." The error related to the reporting of net loss per share after a January 2004 3-for-1 reverse stock split, and forced the company to restate two years' worth of earnings.

"This whole thing brings up the question of whether any of the numbers are real," says Cohan, the venture capitalist. "It seems like it has no cash and it doesn't generate any cash. It survives by convincing credit companies and private investors to give them cash. It's borrowing against receivables."

From June 2004 to June 2005, AHPC's cash balance fell to $16,434 from $359,012. By September it had climbed to $60,000, despite the company posting negative operating cash flow of $755,000 for the quarter.

In September 2004 GE Capital terminated its credit facility with AHPC. This forced the company to work with a privately held commercial financing company called Greenfield Commercial Credit. Greenfield gave the company a $5 million line of credit five months ago and helped with an October private placement of $1.2 million in 7% subordinated promissory notes.

In AHPC's annual report, its accounting firm, Grant Thornton, issued a so-called going concern qualification, meant to warn investors when a company is at risk for eventual insolvency. Last week AHPC fired Grant Thornton and hired independent accounting firm Plante & Moran.

Quote:
"This company reminds me of the company Vandalay Industries, made famous by the 'Seinfeld' TV show," says Cohan. "George, who is trying to get a job, gives Jerry's number for a recommendation, pretending it's a latex firm, Vandalay Industries. The phone rings. Kramer picks it up. George comes out of the bathroom in his underwear screaming, 'Answer Vandalay Industries,' but Kramer says this isn't a company — it's an apartment. Seinfeld then walks in, sees George on the floor in his underwear and says, 'And you want to be my latex salesman?' I think this company has as much a chance of making it as Vandalay Industries."


http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=GLOV.NAS&lColors=0x000000&sSym=GLOV.NAS&hcmask=

http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=GLOV.NAS&lColors=0x000000&sSym=GLOV.NAS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=GLOV.NAS&lColors=0x000000&sSym=GLOV.NAS&hcmask=

[actr]

18.01.2006 08:50
Intel verfehlt im Schlussquartal 05 ... (zwei)
Die niedriger als erwartete Marge begründete Intel (Nachrichten/Aktienkurs) mit der schwächeren Umsatzentwicklung im vierten Quartal. Zudem verwies das Unternehmen auch auf den "leichten Wechsel" im gesamten Produktmix hin zu Produkten, die nicht aus dem Mikroprozessorenbereich stammen sowie auf die Neubewertung bei einem Teil der Lagerbestände. Die effektive Steuerrate sei dagegen mit 29,1% niedriger als erwartet ausgefallen. Intel war von einer Rate von rund 31% ausgegangen.

Die Umsatzentwicklung im Schlussquartal ist den Angaben zufolge vor allem auf geringer als erwartete Auslieferungen und Preise bei Desktop-Prozessoren zurückzuführen. Der Chief Financial Officer des Konzerns, Andy Bryant, sagte im Anschluss an die Ergebnispräsentation, dass sich weitere Faktoren negativ auf das Intel-Geschäft ausgewirkt hätten. So habe es bei der Versorgung mit so genannten Chip Sets Engpässe gegeben.

Bryant zufolge verlor Intel im Schlussquartal geringfügig Marktanteile an Konkurrent Advanced Micro Devices Inc (AMD).

DJG/DJN/abe/nas

[actr]

MORNING UPDATE: Seven Summits Research Issues Alerts for INTC, IBM, YHOO, JPM, and LUV

CHICAGO, Jan 18, 2006 /PRNewswire via COMTEX/ -- Seven Summits Research issues the following Morning Update at 8:30 AM EST with new PriceWatch Alerts for key stocks.
Before the open... PriceWatch Alerts for INTC, IBM, YHOO, JPM, and LUV, Market Overview, News Leaders and Laggards, Today's Economic Calendar, and the Quote Of The Day.

QUOTE OF THE DAY

"We are looking for a new record high in the U.S. trade deficit. The triggers for dollar weakness may come from structural indicators."


-- Todd Elmer, Currency Strategist, Citigroup


New PriceWatch Alerts INTC, IBM, YHOO, JPM, and LUV...

PRICEWATCH ALERTS -- HIGH RETURN COVERED CALL OPTIONS --

-- Intel Corp. (Nasdaq: INTC)

Last Price 25.52 - APR 25.00 CALL OPTION@ $1.70 -> 5.0 % Return assigned*

-- International Business Machines Corp. (NYSE: IBM)

Last Price 83.00 - JUN 80.00 CALL OPTION@ $6.90 -> 5.1 % Return assigned*

-- Yahoo! Inc. (Nasdaq: YHOO)

Last Price 40.11 - FEB 40.00 CALL OPTION@ $2.05 -> 5.1 % Return assigned*

-- JP Morgan Chase & Co. (NYSE: JPM)

Last Price 39.71 - JUN 40.00 CALL OPTION@ $1.70 -> 5.2 % Return assigned*

-- Southwest Airlines Co. (NYSE: LUV)

Last Price 15.87 - JUN 15.00 CALL OPTION@ $1.85-> 7.0 % Return assigned*


MARKET OVERVIEW

Things are looking a bit ugly overseas, as none of the foreign markets we track are in positive territory. Tokyo Stock Exchange officials had to step in and halt trading 20 minutes earlier than normal as a glut of orders threatened to exceed the systems' 4 million-order capacity. This is only the second time that officials have shut down trading early, and it caused many of the major Asian markets to post losses. European shares also moved lower on Wednesday, thanks in part to the situation in Asia and rising oil prices. Every component of the main French and German indices dropped. Oil stocks comprised the scant amount of companies posting gains in Europe.

The February crude contract surged past $66 per barrel yesterday, closing at their highest level since late September. Supply concerns were the main driver for the high prices, as news from Iran and Nigeria sparked worries. The news out of Iran consists of the resumption of its nuclear program. The country denies that it is planning to develop nuclear weapons, but Europe and the United States are trying to call an emergency meeting of the International Atomic Energy Agency, which could result in sanctions against Iran. The country warned that sanctions against it could lead to higher oil prices. In Nigeria, militants have threatened further attacks against the oil industry in the country, which is the world's eighth-largest oil exporter. A glut of attacks against Royal Dutch Shell facilities have caused the company to cut output and withdraw staff from four oil production platforms.


2006 has started well for the OPEC oil nations -- the cartel that controls about 40% of the world's oil output. And according to the US Department of Energy, it's set to increase its revenues by 10% to a record US$522 billion this year. They barely look worse off in 2007, with revenues projected to drop only slightly to US$495 billion. Elsewhere on the power-generating topic, General Electric, Siemens and Alstom have released a combined report detailing how they believe the world is about to experience a power shift from gas to coal. Their research, obtained by the Financial Times, shows that they expect 40% of the new orders for electric turbines over the next decade to be for coal-powered systems. Meanwhile, demand for gas-based systems is expected to drop some 25-30%. So why the shift? Well, there are several reasons. Unsurprisingly, the biggest concern is that gas is becoming increasingly expensive because of supply concerns. Proof of this was seen just recently, as Russia and the Ukraine became embroiled in a dispute over pricing. In addition, new technological advances mean coal is now less of a pollutant that before. Over in Japan, the prospects for more sustained growth are looking brighter. In its new report outlining the state of the country's economy, the Bank of Japan said that all nine regions announced positive data for the final quarter of 2005. Back in October, six of the nine upgraded their outlooks. Conclusion? That, coupled with a statement from Governor Toshihiko Fukui last week that the country is emerging from its prolonged black hole of deflation, Japan's economy has turned the corner.

Read more economic/market/stock analysis from the Taipan Group and 247Profits.com every trading day with the FREE 247Profits Dynamic Market Alert. Featuring: insightful economic commentary from the US and worldwide... profitable investment recommendations...and full access to the leading team of financial experts. Register for free here: http://www.247profits.com/enter.html

NEWS LEADERS AND LAGGARDS

So far today, J.P. Morgan Chase, Southwest Airlines, and Mellon Financial lead the list of companies with the most news stories while SunTrust Banks and Sony Ericsson Mobile are showing a spike in news. CIT Group, International Business Machines, and Johnson & Johnson have the highest srtIndex scores to top the list of companies with positive news while Intel and Yahoo! lead the list of companies with negative news reports. Bank of New York has popped up with a high positive news sraIndex score.


TODAY'S ECONOMIC CALENDAR

7:00 a.m. Jan 13 MBA Refinancing Index

7:45 a.m. Jan 14 ICSC Store Sales Index

8:30 a.m. Dec CPI

8:30 a.m. Dec CPI, ex-food and energy

8:55 a.m. Jan 14 Redbook Retail Sales Index

9:00 a.m. Nov Treasury Intl Capital Flows

12:15 p.m. Richmond Fed Pres Lacker speaks in Baltimore

1:00 p.m. Jan NAHB Housing Index

2:00 p.m. Federal Reserve Beige Book

[actr]

Ivanhoe Energy, Inc. - Common Shares
18.01.06 19:40 Uhr

2,87 USD

+20,59 % [+0,49
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=IVAN.NAS&lColors=0x000000&sSym=IVAN.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=IVAN.NAS&lColors=0x000000&sSym=IVAN.NAS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=IVAN.NAS&lColors=0x000000&sSym=IVAN.NAS&hcmask=

Börse
NASDAQ

Aktuell
2,87 USD

Zeit
18.01.06 19:40

Diff. Vortag
+20,59 %

Tages-Vol.
129,31 Mio.

Gehandelte Stück
48 Mio.

Conference Call Wednesday, January 18, to discuss Ivanhoe Energy's Heavy-to-Light Oil process

BAKERSFIELD, CA, Jan 18, 2006 /PRNewswire-FirstCall via COMTEX/ -- Ivanhoe Energy Inc. (NASDAQ: IVAN and TSX: IE, IE.U) will host a telephone conference call for investors and analysts today, Wednesday, January 18, at 4:00 p.m. EST (1:00 p.m. PST).
Briefings will be provided on the successful attainment of performance objectives by the company's Commercial Demonstration Facility in Southern California that is showcasing Ivanhoe's revolutionary heavy-oil upgrading technology (HTL). Ivanhoe Energy now is preparing to test crudes from potential partners, with an initial focus on heavy crudes from California and Western Canada, including bitumen from Canada's Athabasca Tar Sands region.


Ivanhoe Energy is an independent international oil and gas exploration and development company building long-term growth in its reserve base and production. Ivanhoe Energy is a leader in technologically innovative methods designed to significantly improve reserves of oil and gas through the upgrading of heavy oil to light oil, state-of-the-art drilling techniques, enhanced oil recovery (EOR) and the conversion of natural gas to liquids (GTL). Core operations are in the United States and China, with business development opportunities worldwide.

Ivanhoe Energy trades on the NASDAQ Capital Market with the ticker symbol IVAN and on the Toronto Stock Exchange (TSX) with the symbol IE.

[actr]

NAUTILUS INC
18.01.06 20:11 Uhr

13,969 USD

-24,61 % [-4,561]
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=NLS.NYS&lColors=0x000000&sSym=NLS.NYS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=NLS.NYS&lColors=0x000000&sSym=NLS.NYS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=NLS.NYS&lColors=0x000000&sSym=NLS.NYS&hcmask=

Börse
NYSE

Aktuell
13,969 USD

Zeit
18.01.06 20:11

Diff. Vortag
-24,61 %

Tages-Vol.
119,15 Mio.

Gehandelte Stück
9,1 Mio.



Nautilus, Inc. Announces Preliminary Fourth Quarter 2005 Results

VANCOUVER, Wash., Jan 18, 2006 (BUSINESS WIRE) -- Nautilus, Inc. (NYSE:NLS), a leading marketer, developer, and manufacturer of branded health and fitness products, today provided preliminary fourth quarter 2005 results, and announced the date of its next quarterly conference call with investors.
Based upon preliminary information, the Company announced that it expects fourth quarter 2005 net sales in the range of $179-183 million, with corresponding earnings per share in the $0.07-0.12 range. The Company's previous fourth quarter 2005 guidance presented on November 2, 2005, estimated net sales of $210 million and earnings per share in the $0.44-0.48 range.

"Our innovation-centered business model generated increasing consumer interest in our products again in the fourth quarter, helping us achieve net sales growth of 21 percent in fiscal 2005," said Gregg Hammann, Chairman and Chief Executive Officer. "However, we are experiencing growing pains in ramping innovation through the manufacturing side of our business, which resulted in delays in the introduction of new products that were expected to have significant sales and earnings in the fourth quarter. We are continuing to make progress in improving our manufacturing and operational capacity as we adjust to a fast pace of product innovation. We are closing gaps and improving efficiencies in each stage of our go-to-market process."

The Company continues to expect 15-20 percent annualized sales growth, and 20-30 percent annualized earnings growth, through its 2006-08 strategic business plan.

The fourth quarter 2005 conference call is scheduled for 5 p.m. EST (2 p.m. PST) February 1, 2006. It will be broadcast live over the Internet hosted at www.nautilusinc.com/events and will be archived online within one hour after completion of the call. In addition, listeners may call 800-729-5806 from anywhere in North America, and 212-676-4919 from outside North America. Participants will include: Gregg Hammann, Chairman and Chief Executive Officer; Bill Meadowcroft, Chief Financial Officer; and Tim Hawkins, Chief Customer Officer and Chief Marketing Officer.

A telephonic playback will be available from 7:00 p.m. PST February 1 through 7:00 p.m. PST, February 10, 2006. North American callers can dial 800-633-8284 and other international callers can dial 402-977-9140 to hear the playback. The passcode is 21282027.

About Nautilus, Inc.

Headquartered in Vancouver, Wash., Nautilus, Inc. (NYSE:NLS) is a pure fitness company that provides tools and education necessary to help people achieve a fit and healthy lifestyle. With a brand portfolio that includes Nautilus(R), Bowflex(R), Schwinn(R)Fitness, StairMaster(R), Trimline(R) and Pearl iZUMi(R), Nautilus manufactures and markets a complete line of innovative health and fitness products through direct, commercial, retail, specialty and international channels. The Company was formed in 1986 and had sales of $524 million in 2004. It has 1,400 employees and operations in Washington, Oregon, Colorado, Oklahoma, Texas, Illinois, Virginia, Canada, Switzerland, Germany, United Kingdom, Italy, China, and other locations around the world. More information is at www.nautilusinc.com.

[actr]

Intel Corporation
18.01.06 21:10 Uhr

22,51 USD

-11,79 % [-3,01]
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=INTC.NAS&lColors=0x000000&sSym=INTC.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=INTC.NAS&lColors=0x000000&sSym=INTC.NAS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=INTC.NAS&lColors=0x000000&sSym=INTC.NAS&hcmask=

Börse
NASDAQ

Aktuell
22,51 USD

Zeit
18.01.06 21:10

Diff. Vortag
-11,79 %

Tages-Vol.
4,93 Mrd.

Gehandelte Stück
244 Mio.

Despite its third straight year of double-digit earnings growth, Intel reportedly disappointed many Wall Street analysts that expected better numbers from the world's leading computer chip maker.

[actr]

Yahoo! Inc.
18.01.06 21:18 Uhr

35,24 USD

-12,14 % [-4,87]
KGVe:
46,99

http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=YHOO.NAS&lColors=0x000000&sSym=YHOO.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=YHOO.NAS&lColors=0x000000&sSym=YHOO.NAS&hcmask=
http://isht.comdirect.de/charts/large.chart?hist=6m&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=YHOO.NAS&lColors=0x000000&sSym=YHOO.NAS&hcmask=

Börse
NASDAQ

Aktuell
35,26 USD

Zeit
18.01.06 21:19

Diff. Vortag
-12,09 %

Tages-Vol.
3,38 Mrd.

Gehandelte Stück
103 Mio

Yahoo Profit Jumps; Shares Slide

United States, Jan 18, 2006 (Newsbytes via COMTEX) -- Yahoo Inc. said yesterday that its fourth-quarter profit nearly doubled and revenue was up almost 40 percent, but Wall Street viewed the earnings report as disappointing and sent the Web portal's stock tumbling by more than 13 percent in after-hours trading.
For the quarter that ended Dec. 31, Yahoo said it earned $683.2 million, compared with $372.5 million for the comparable period in 2004. For the 2005 fiscal year, the Sunnyvale, Calif.-based company earned $1.9 billion, compared with $839.6 million the previous year.

Yahoo executives credited the increase to advertisers moving to the Internet and said advertiser spending could double for the company within the next two years.

Analysts agreed that online advertising sales in the United States would probably see substantial increases, with the fastest growth coming from search-based ads. In that arena, Yahoo's market share slipped to 19 percent in November from 27 percent a year earlier. Google Inc. saw its share jump to 60 percent from 47 percent.

Financial analysts had expected earnings of 17 cents per share, excluding one-time gains and tax benefits. Yahoo missed that forecast by a penny, and its stock plummeted $5.15 in after-hours trading to $34.96.

Simply, analysts said, Yahoo's quarter wasn't good enough to wow Wall Street.

"What's disappointing about it is they didn't really trump people's expectations," said Oppenheimer & Co. analyst Sasa Zorovic. "People are now saying: 'Look, I was anticipating more. I didn't get what I anticipated, so I'm going to scale back.'

"For Yahoo, people always hope they will become more like Google, and this quarter was not Google-like," he said. "Google definitely beats and raises expectations. Yahoo was more ho-hum in that sense

[actr]

Stereotaxis, Inc.
18.01.06 21:24 Uhr

13,33 USD

+14,62 % [+1,70]
http://isht.comdirect.de/charts/big.chart?hist=1d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=STXS.NAS&lColors=0x000000&sSym=STXS.NAS&hcmask=
http://isht.comdirect.de/charts/big.chart?hist=10d&type=CONNECTLINE&ind0=VOLUME&&currency=&&lSyms=STXS.NAS&lColors=0x000000&sSym=STXS.NAS&hcmask= http://isht.comdirect.de/charts/large.chart?hist=10d&type=candle&asc=lin&dsc=abs&avgtype=simple&ind=BB&ind0=VOLUME&ind1=RSI&&currency=&lSyms=STXS.NAS&lColors=0x000000&sSym=STXS.NAS&hcmask=

Börse
NASDAQ

Aktuell
13,33 USD

Zeit
18.01.06 21:24

Diff. Vortag
+14,62 %

Tages-Vol.
13,44 Mio.

Gehandelte Stück
1,1 Mio.

Stereotaxis Announces Initial U.S. Clinical Usages of Cardiac Ablation Catheter With Company's Niobe(R) System - Significant Milestone Achieved With Successful Complex Ablations Completed at Three Leading U.S. Electrophysiology Centers Utilizing the

ST. LOUIS, Mo., Jan 12, 2006 /PRNewswire-FirstCall via COMTEX/ -- Stereotaxis, Inc. (Nasdaq: STXS) today announced the achievement of a significant milestone with three leading electrophysiology sites becoming the first U.S. centers to successfully treat cardiac arrhythmias using the Celsius(R) RMT Diagnostic and Ablation Catheter. This proprietary catheter, which was co-developed by Stereotaxis and Biosense Webster, recently received FDA approval for use with the Stereotaxis Niobe(R) Magnetic Navigation System. This expands applications of the Stereotaxis Niobe System in the U.S. from diagnostic and device delivery procedures into the major therapeutic market for minimally invasive endocardial ablation treatment of cardiac arrhythmias. The worldwide market for these procedures is experiencing rapid growth and Stereotaxis estimates that the market currently comprises more than 400,000 procedures per year, of which approximately 70% are conducted in the U.S.
During the week of January 2, Cleveland Clinic, Baptist Memorial Hospital-Memphis and St. Elizabeth's Medical Center of Boston completed a total of 15 procedures with the Stereotaxis Niobe system, including successful completion of complex AVNRT ablation, AV node ablation, Atrial Tachycardia Ablation and treatment of Wolff-Parkinson-White Syndrome, as well as a number of Bi-Ventricular pacing lead placements for treatment of Congestive Heart Failure. The Cleveland Clinic procedures, which included a complex atrial tachycardia, were successfully completed in the Cleveland Clinic's department of Cardiovascular Medicine, section of Electrophysiology and Pacing, which is co-chaired by Dr. Andrea Natale, M.D., and Patrick Tchou, M.D. Dr. Tchou performed the ablation utilizing Stereotaxis' Niobe Magnetic Navigation system to successfully complete the ablation.

"The Stereotaxis system marks a fundamental change in the way we can treat cardiac arrhythmias," said Dr. Tchou. "During the successful treatment of a patient with an atrial tachycardia, we were able to precisely and easily adjust the tip of the Celsius RMT Diagnostic and Ablation Catheter using computer control. The catheter maintained an extraordinarily consistent contact with the tissue during the application of energy that is not generally achieved in manual ablation. Consistent contact is a critical element to the success of the ablation."

"Until today, in order to map and ablate arrhythmia, it was necessary to manually advance and rotate a fairly stiff catheter in an effort to reach specific points within the heart," said Dr. Natale. "Adding computer control and automation to precisely steer soft, magnetically enabled catheters offers the potential to improve the treatment of complex arrhythmia. We look forward to treating a wide range of arrhythmias with this enhanced technology."

Eric Johnson, M.D., of Baptist Memorial Hospital, successfully completed two AV node ablations with the Stereotaxis system in combination with the Celsius RMT Diagnostic and Ablation Catheter. "The decreased procedure time and increased efficiency seen in our initial experiences using the Stereotaxis system in combination with the Celsius RMT Diagnostic and Ablation Catheter are rarely achieved when relying on manual ablation," said Dr. Johnson. "At a community hospital, speed and efficiency are obviously critical to the center's ability to increase patient volume, and I believe that leveraging this technology could be helpful in increasing patient flow."

Charles I. Hafajee, M.D., of St. Elizabeth's Medical Center commented, after completing successful ablation procedures with the Celsius RMT Diagnostic and Ablation Catheter, "I am very impressed with the combination of the Stereotaxis system and the new mapping and ablation catheters. The system is intuitive, user-friendly and enables us to reproduce accurate and detailed maps of cardiac anatomy."

Physicians in Europe have been able to utilize the Celsius RMT Ablation Catheter with the Niobe system since CE Mark authorization was received in March 2005 and have conducted successful ablation procedures for a variety of arrhythmias, including Wolff-Parkinson-White Syndrome, AVNRT and AVRT.

The Niobe system utilizes a computer-controlled magnetic field to remotely steer a magnetic catheter or other device through the vasculature to the target therapy site and to apply therapy with precision and efficiency, utilizing sophisticated integration of major imaging technologies. Additionally, clinical feedback indicates that use of the Niobe system reduces physician exposure to imaging radiation during procedures and that the system enhances patient safety because the consistent, "soft-touch" contact with the heart wall unique to magnetically enabled catheters may reduce the risk of vessel or other tissue perforation during procedures. The core components of the Stereotaxis system have received regulatory clearance in the U.S. and Europe.

"The use of magnetic navigation to precisely control the therapeutic tip of soft ablation catheters is a fundamental improvement over the existing practice of physicians manually controlling devices that are difficult to manipulate," said Bevil Hogg, President and CEO of Stereotaxis. "We firmly believe that Stereotaxis has the potential to become the new standard of care for both routine and highly complex ablation and other cardiac procedures."

[actr]

One Rep Too Many

By Lawrence Carrel
January 18, 2006


--------------------------------------------------------------------------------
Nautilus, Inc. (NLS1)

--------------------------------------------------------------------------------
Share price as of Tuesday's close: $18.53
Share price now: $13.91
Change: -24.9%
Volume: 11.6 million shares, daily average 693,500 shares
Last time this low: Jan. 29, 2004
52-week high: $29.65
52-week low: $16.70
Forward P/E before announcement: 15.4 (based on $1.20 a share)
Forward P/E after announcement: 16.2 (based on 86 cents a share)

--------------------------------------------------------------------------------

THE PRICE OF NAUTILUS (NLS2) stock plummeted like a weight stack with a slipped pin Wednesday.
Shares of the manufacturer of health and fitness products fell 25% to a two-year low of $13.91 after the Vancouver, Wash., company warned manufacturing problems would cause fourth-quarter earnings to come in 75% below its previous guidance. Despite plenty of consumer interest for its new products, Ron Arp, Nautilus's director of communications, says production bottlenecks put a damper on results.

" The ramp-out in terms of quantity available for sale proceeded much more slowly than expected; therein lies the shortfall," says Arp. " I would present this as growing pains in a company that seeks to grow its product offerings. It's about a commitment to get it right the first time, and we ended up not selling the kind of volume we expected, despite the fact there was strong consumer interest. We just couldn't meet demand."

The reason Nautilus didn't see the shortfall earlier in the quarter, says Arp, was because half of all fourth-quarter sales occur in December, with a large part coming right before Christmas through New Year's Day, as people make resolutions to exercise more. And while the company may have lost some sales to competitors, Arp says products have a three- to four-year life cycle and that " the market place is hungry for new fitness equipment."

Nautilus now expects fourth-quarter earnings to total between seven cents and 12 cents a share on net sales of $179 million to $183 million. That bears little similarity to the company's November guidance of profits between 44 cents and 48 cents on $210 million in revenues. Thomson First Call had a consensus estimate of 46 cents. The November guidance, too, was the result of a warning; previously the company had said it would earn 55 cents to 57 cents a share. In the year-ago fourth quarter Nautilus earned $14.2 million, or 42 cents, on sales of $169.6 million.

" The company didn't hold a conference call, so it's very hard to get a hold of what caused a $25 million to $30 million top-line shortfall," says Marc Bettinger, an analyst at Stanford Group, an investment bank based in Boca Raton, Fla. " I understand we're talking about a manufacturing issue related to new products, but why this occurred and the planning involved remains unanswered. What steps are being taken to resolve it?" On Wednesday, Bettinger cut his rating on the stock to Hold from Buy.

Nautilus said it was in the process of improving manufacturing and operational capacity, but spokesman Arp declined to offer specifics. Among the 20-year-old company's fitness products are its namesake brand of commercial gym machines, Bowflex home gym equipment, Schwinn Fitness exercise bikes, StairMaster step machines, Trimline treadmills and Pearl iZUMi sports apparel, as well as nutritional supplements. In 2004 Nautilus posted sales of $524 million.

" Management clearly will need to enact significant changes to the company's supply chain to not only address such a lack of operational efficiency in the near term, but to also ensure such problems do not arise in the future," wrote Rommel Dionisio, an analyst at Los Angeles investment bank Wedbush Morgan Securities, on Wednesday. " We still believe that management has done an impressive job of growing the top line in recent quarters, through gaining important new retail customers as well as successful new product introductions. However, it now becomes clear that the company's supply chain and production infrastructure were not up to the challenge of keeping pace with such increased demand."
Dionisio said typically when such significant operational challenges occur in the consumer-products industry, it requires at least two quarters to fix the problems. Accordingly, he cut his rating on the stock to Hold from Buy.

Despite the fourth-quarter stumble, Nautilus reiterated its forecast for 20% to 30% annualized earnings growth on 15% to 20% annualized sales growth from 2006 through 2008. The company expects to release final results on Feb. 1.

In 2002, Nautilus posted record earnings of $98 million. But investors who bought shares at the start of that year had lost 55% two years later. For most of 20033 sales and earnings plunged on what the company called a " challenging business environment4."

The company said it completed a turnaround in 2004 and that 2005 was expected to be a year of growth and investment in the future. But with the stock down nearly 60% from its midyear high of $29.65, some might say the company is still in turnaround mode.

Part of the past year's selloff related to Nautilus being found liable for falsely advertising its Bowflex home gym over a 17-year period. In November, a jury in federal court in Salt Lake City found the company misled customers by saying Bowflex had " patented power rods," when it really was a patented product that used power-rod technologies. A judge is currently reviewing the $7.8 million judgment.

Quote:
" If demand wasn't there I would be concerned, but demand is strong," says Eric Wold, an analyst at San Francisco investment bank Merriman Curhan Ford & Co. " The problem is Nautilus is launching too many new products in too short a period of time. Also, I think there is a big misunderstanding from the press release. The company is expected to earn 70 cents in fiscal 2005 and people are forecasting 2006 earnings of 85 cents to 90 cents. However, management thinks the manufacturing problem is a one-time thing. So, the 30-cent earnings hit for 2005 should be added back in, for a total of $1 a share, before looking for 20% to 30% earnings growth. That means 2006 should see earnings between $1.20 and $1.30 a share."

[actr]

Dynavax's Ragweed Allergy Therapy, TOLAMBA(TM), Achieves Primary Efficacy and Safety Endpoints in Phase 2/3 Trial Statistical Significance Achieved in Primary Endpoint (p=0.024) and Major Secondary Endpoints; Pivotal Phase 3 Trial Anticipated to Begi

BERKELEY, Calif., Jan 18, 2006 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that results from a two-year Phase 2/3 clinical trial of TOLAMBA, a ragweed allergy immunotherapeutic, showed that patients treated with TOLAMBA experienced a statistically significant reduction in total nasal symptom scores (TNSS) compared to placebo-treated patients in the second year of the trial, the primary efficacy endpoint of the study (p=0.024). Results also showed significant clinical benefit relative to secondary endpoints, including composite hay fever symptoms and ocular effects, and a significant reduction in antihistamine use (p=0.01). These results were achieved after a single short course of therapy prior to the first ragweed season (2004), and demonstrated that a booster dose prior to the second season (2005) was not required to achieve clinical benefit. Unlike the TOLAMBA-treated group, the boosted group did not achieve statistical significance relative to the primary efficacy endpoint compared to placebo. The safety profile of TOLAMBA was favorable. Systemic side effects were indi